CSPC Pharmaceutical (HKG:1093) said its subsidiary CSPC Innovation has submitted a listing application to the Hong Kong Stock Exchange for its proposed H-share listing, according to a Thursday bourse filing.
CSPC Innovation is expected to remain an indirect subsidiary after the listing.
Key details, including the timetable, offer size, and structure, have not yet been finalized, the filing added.
Completion of the listing remains subject to market conditions and approvals from regulators.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments